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Verapamil is a newly marketed antiarrhythmic drug. It has a significant pre- 
systemic elimination when administered orally and, therefore, intravenous 
therapy is often recommended. Optimum therapeutic effect is obtained when 
verapamil plasma concentrations are between 100 and 400 ng/ml. 
Several chromatographic procedures for the determination of verapamil in 
biological fluids have been described in the literature [l-11]. Some of the 
procedures have also quantitated verapamil metabolites [l, 6, 7 1. The high- 
performance liquid chromatographic (HPLC), as well as the gas-liquid chro- 
matographic (GLC) procedures are sensitive but require lengthy and tedious 
multiple extraction steps especially when the metabolites are quantitated. 
This report describes a rapid, sensitive and accurate GLC procedure with 
thermionic specific detection for the determination of verapamil in dog plasma. 
This procedure also has a potential use in controlled clinical pharmacokinetic 
studies of this antiarrhythmic agent in humans. 
MATERIALS AND METHODS 
Reagents 
Ethyl acetate, diethyl ether, pentane (Burdick & Jackson Labs., Muskegon, 
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MI, U.S.A.), sodium hydroxide (Fisher Scientific, Fairlawn, NJ, U.S.A.), 
verapamil hydrochloride (Knoll Pharmaceuticals, Whippany, NJ, U.S.A.), and 
l-(diethylaminoethyl)-~(p-ethoxybenzyl)-5nitrobenzimidazole. HCI, the in- 
ternal standard, were used. 
Stock solutions 
Verapamil stock solution. Verapamil l HCl (10.0 mg) was dissolved in 100 
ml methanol to yield a stock solution containing 100 pg/ml verapamil l HCl. 
Internal standard stock solution. Internal standard (25.0 mg) was dissolved 
in 25 ml ethyl acetate to yield a stock solution containing 1.0 mg/ml internal 
standard. 
Standards 
Verapamil standard solution. The verapamil stock solution was diluted 1:5 
to yield a 20 pg/ml verapamil l HCl standard solution. 
Internal standard solution. The internal standard stock solution (50 ~1) 
was diluted to 5 ml to yield a 10 pg/ml internal standard solution. 
Quality-control samples 
To a 25-ml volumetric flask, 750 ~1 of the verapamil standard solution (20 
pg/ml) were added and the final volume adjusted to 25 ml by addition of blank 
plasma. After mixing, 1.25-ml aliquots were transferred to glass tubes, tightly 
capped and stored frozen at -20” C until use. Each quality-control sample con- 
tained 600 ng/ml verapamil. Of the sample 1 ml was used for analysis. 
Chromatographic conditions 
The gas chromatograph (Varian Model 3700) was equipped with a 
thermionic specific detector and a deactivated, silylated glass column (1.2 m 
X 2 mm I.D., 6 mm O.D.) packed with 1% OV-1 on 60-80 mesh Gas-Chrom Q. 
The carrier gas was pre-purified nitrogen set to a flow-rate of 30 ml/min. The 
air flow-rate to the detector was adjusted to 175 ml/min and the hydrogen 
flow-rate was set to 4.5 ml/min. The bead current and bias voltage settings were 
470 and 4, respectively. The electrometer attenuation was set at 2-8 * lo-“. 
The gas chromatograph operating conditions were: injector temperature, 
28O”C, column temperature, 25O”C, and the detector temperature, 280°C. 
The column was conditioned at 270°C for 24 h. 
Sample preparation 
To glass tubes (15 ml capacity) were added 1 ml plasma, 50 ~1 internal 
standard solution, 50 ~1 sodium hydroxide (10 M) and 7.5 ml pentane-diethyl 
ether (70:30). The tubes were tightly capped and shaken for 15 min. The tubes 
were then centrifuged at 1000 g for 10 min (room temperature) and 6.0 ml of 
the organic phase (upper layer) were transferred to clean glass tubes and 
evaporated to dryness at 40°C with a stream of air. The residue was then re- 
constituted in 100 ~1 ethyl acetate and 2.0 ~1 were injected for GLC analysis. 
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RESULTS AND DISCUSSION 
Typical chromatograms of a calibration standard (100 ng/ml verapamil), 
a pre-dose (blank) sample from an experimental subject (dog), and a plasma 
sample obtained from that subject after the intravenous (i.v.) administration of 
verapamil are shown in Fig. 1. Blank plasma did not have any interfering peaks 
as is evident from Fig. la. Retention times of verapamil and the internal 
standard were 1.7 and 2.5 min, respectively. The validity of the assay 
procedure was established through a study of linearity of response, 
reproducibility, accuracy and precision. 
Standard calibration curves corresponding to verapamil concentrations of 
0.0, 50.0, 100.0, 200.0, 400.0,600.0, 800.0, and 1000.0 ng/ml of plasma were 
prepared by adding appropriate volumes of the verapamil standard solution to 
tubes containing 1.0 ml blank plasma. The standard calibration curve was 
prepared by plotting peak height ratios (verapamil:internal standard) as a 
function of the verapamil concentration. The calibration curve was found to be 
linear over the verapamil concentration range of 50--1000 ng/ml. The best-fit 
least-squares line was obtained by using a calibration curve program on the 
Apple II plus microcomputer. The data best fit a straight line. The correlation 
coefficients for inter-day standard calibration curves ranged from 0.9955 to 
0.9989. The coefficients of variation (C.V., %) calculated from the inversely 
estimated concentrations for inter-day standard calibration curves ranged from 
4.87% to 6.82%. The intra-day reproducibility of the calibration samples had 
C.V. values ranging from 1.11% to 9.31% as shown in Table I. 
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Fig. 1. Typical chromatograms representing (a) a calibration standard containing 100 ng/ml 
verapamil in plasma, (b) a pre-dose (blank) sample from the experimental subject (dog), 
and (c) a plasma sample obtained from the same subject following the iv infusion of 
verapamil (0.267 mg/kg/min for 3.0 min). Peaks: V, verapamil; IS, internal standard. 
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TABLE I 
INTRA-DAY REPRODUCIBILITY OF THE ASSAY 
Each peak height ratio was obtained from an independently prepared calibration sample; all 
samples were assayed on the same day. 
Concentration Peak height ratio Mean + S.D. Coefficient of 
(ng/mI) variation (%) 
50 0.147 0.176 0.170 0.1643 ? 0.0153 9.31 
100 0 300 0.300 0.294 0.298 + 0.003 1.11 
200 0.500 0.609 0.579 0.582 f 0.0247 4.24 
400 1.154 1.224 1.25 1.209 + 0.049 4.10 
600 1.704 1.818 1.817 1.779 + 0.065 3.68 
800 2.385 2.481 2 387 2.417 + 0.0548 2.26 
1000 2.758 3.08 2.963 2.9: + 0.163 5.5 
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Fig. 2. The plasma concentration-time profile in a dog following a short i.v. infusion of 
verapamil (0.267 mg/kg/min for 3.0 min). 
The accuracy of the method was assessed by analyzing quality-control 
samples on each assay day. The quality-control sample variability was found to 
have a C.V. of 9.26% and a mean concentration of 592.7 ng/ml with the 
theoretical concentration being 600 ng/ml. 
Application of the method developed was demonstrated by measuring 
plasma levels of verapamil in dogs after a short i.v. infusion of verapamil. The 
plasma concentration-time profile of verapamil obtained in one such pharma- 
cokinetic study is shown in Fig. 2. The post-infusion data are well described 
by the following polyexponential equation: 
C = 24,$Oe-0.1583t + 125,4e-0.0’77t 
The distribution half-life (tl/aa) of verapamil was 4.4 min and the terminal half- 
life (tsp) was 39 min. 
Several analytical methods for verapamil determination require multiple 
extraction steps [5- 7, 9, 101 and are, therefore, time-consuming. The HPLC 
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procedures described in the literature [5, 6, 8-101 require longer chromato- 
graphic separation time as compared to the GLC method reported here. Several 
HPLC methods allow the determination of verapamil and some of its metab- 
olites. However, only norverapamil has been shown to possess some biological 
activity. Although this method has not been applied for the determination of 
verapamil levels in clinical studies involving humans, the calibration samples 
and assay validation studies utilized both human and dog blank (control) 
plasmas interchangeably, and no interfering peaks were seen. The authors 
will be using this procedure for the determination of verapamil levels in plasma 
samples from a controlled clinical trial. Also, the sensitivity, precision and 
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